We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
As pressure continues to build on drugmakers to address high drug prices, Eli Lilly announced that it will market a half-priced generic of its Humalog insulin injection in the U.S. Read More
Novartis filed a lawsuit on Friday accusing Janssen of falsely claiming that its plaque psoriasis drug Tremfya (guselkumab) is superior to Novartis’ product, Cosentyx (secukinumab). Read More
The FDA required a clinical trial among rheumatoid arthritis patients to test the risk of heart problems, cancer and opportunistic infections. Read More
One committee member voted “no” on the delay, saying “we do patients some potential benefit here if this agent is used constructively and intelligently while we wait for additional data.” Read More
The scheme involved fraudulent claims submissions to Medicare Part D plan sponsors for drugs that the pharmacy never ordered or dispensed to beneficiaries. Read More
A class action lawsuit filed in California claims Genentech took advantage of cancer patients by packaging oncology drugs in oversized vials. Read More
Several pharma industry trade groups and drugmakers wrote to the FDA to endorse a Pfizer petition asking the agency to take more aggressive steps against biosimilar-related misinformation. Read More
The FDA has issued final guidance clarifying its thought process for evaluating bulk drug substances that are being considered for the 503B bulks list, which specifies substances that outsourcing facilities may use in drug compounding. Read More
When food adversely affects a drug’s safety or efficacy, requiring fasted dosing, the sponsor should conduct studies to determine a realistic time interval between drug dosing and meals, the guidance states. Read More